Functional Dyspepsia Market Insights

DelveInsight’s ‘Functional Dyspepsia—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Functional Dyspepsia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted Functional Dyspepsia symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Functional Dyspepsia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Functional Dyspepsia Disease Understanding and Treatment Algorithm

Functional Dyspepsia Overview

Dyspepsia is a constellation of symptoms predominantly in the gastroduodenal region of the upper gastrointestinal tract. Functional dyspepsia is defined as at least 1 month of epigastric discomfort without evidence of organic disease found during an upper endoscopy, and it accounts for 70% of dyspepsia. The Rome diagnostic criteria classified Functional dyspepsia into two non-exclusive subtypes: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS).


The key symptoms of Functional dyspepsia are early satiety, postprandial fullness, epigastric pain, or burning. Other symptoms may include nausea, vomiting, loss of appetite. Though Functional dyspepsia is a prevalent functional gastrointestinal disorder (FGID), it is often difficult to diagnose as it is caused by heterogeneous factors. The major pathogenesis of Functional dyspepsia includes infectious and post-infectious changes in the gut, abnormal gastric motility, visceral hypersensitivity, and psychosocial and genetic factors.


Functional Dyspepsia Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Functional Dyspepsia market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Functional Dyspepsia market report thoroughly understands Functional Dyspepsia symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Functional Dyspepsia treatment algorithms and treatment guidelines for Functional Dyspepsia symptoms in the US, Europe, and Japan.


Management of dyspepsia symptoms relies upon pharmacologic treatments and non-pharmacologic approaches, including psychological and complementary interventions.


Eradication therapy should be offered to patients with functional dyspepsia who test positive for Helicobacter pylori. Other therapies with evidence of effectiveness include proton pump inhibitors, histamine-2 receptor antagonists, prokinetics, and central neuromodulators. However, the role of psychological therapies remains unclear.

Functional Dyspepsia Epidemiology

The Functional Dyspepsia symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.


Key Findings

The total incident cases of Functional Dyspepsia is increasing by 7MM during the study period, i.e., 2018–2030.


]The disease epidemiology covered in the report provides historical as well as forecasted Functional Dyspepsia symptoms epidemiology segmented as the Prevalence of Functional dyspepsia, Type-specific cases of Functional dyspepsia, Age-specific Cases of Functional dyspepsia, and Gender-specific cases of Functional dyspepsia. The report includes the prevalent scenario of Functional Dyspepsia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Functional Dyspepsia Epidemiology

The epidemiology segment also provides the Functional Dyspepsia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total number of prevalent cases of Functional Dyspepsia associated in 7MM countries was 48,959.8 in 2020.

Functional Dyspepsia Drug Chapters

The Functional Dyspepsia report’s drug chapter segment encloses the detailed analysis of Functional Dyspepsia early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Functional Dyspepsia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Functional Dyspepsia Emerging Drug


Motilitone (DA-9701): Dong-A ST

Motilitone (DA-9701) is a new herbal drug consisting of Corydalis Tuber and Pharbitidis Semen, which has been developed to treat functional dyspepsia. The heterogeneous symptom pattern and multiple causes of functional dyspepsia have resulted in numerous drug target strategies for its treatment. DA-9701, with its multiple mechanisms of action, such as fundus relaxation, visceral analgesia, and prokinetic effects, improves functional dyspepsia symptoms in affected patients. While its safety profile is preferable to other treatments, its pharmacological effects also include conventional effects, such as enhanced gastric emptying and gastrointestinal transit.


Currently, the molecule is in the developmental phase in the United States, and Phase II was completed in 2018.

Products detail in the report…

Functional Dyspepsia Market Outlook

The report’s Functional Dyspepsia market outlook helps build a detailed comprehension of the historic, current, and forecasted Functional Dyspepsia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Functional Dyspepsia market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.


According to DelveInsight, the Functional Dyspepsia market in 7MM is expected to grow in the study period 2018–2030.


Due to the diverse clinical manifestations of Functional dyspepsia, for a majority of patients, the treatment is symptom-based. Eradication therapy should be offered to patients with Functional dyspepsia who test positive for H. pylori. Other therapies with evidence of effectiveness include proton pump inhibitors, histamine-2 receptor antagonists, prokinetics, and central neuromodulators. Though psychological therapies are helpful in some cases, psychological therapies as a clinical guideline are uncertain.


Key Findings

This section includes a glimpse of the Functional Dyspepsia market in 7MM.


Functional Dyspepsia market size in the seven major markets was USD 1,799.9 million in 2020.


The United States Market Outlook

This section provides the total Functional Dyspepsia market size and market size by therapies in the United States.


The United States accounts for the largest market size of Functional Dyspepsia in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Functional Dyspepsia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Functional Dyspepsia market Size and market Size by therapies in Japan are also mentioned.

Functional Dyspepsia Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Functional Dyspepsia market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Functional Dyspepsia Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Functional Dyspepsia key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Functional Dyspepsia emerging therapies.

Reimbursement Scenario in Functional Dyspepsia

Approaching reimbursement proactively can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


The high treatment costs, including chemo and other therapies, affect patients’ affordability and access to these treatment options. Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the drug price relative to the benefit it produces in treated patients.


The disease advocacy groups working in the area of Functional dyspepsia helps patients with medical billing, insurance coverage, and reimbursement issues. Also, financial assistance is available from both governments and pharmaceutical companies to help people who cannot afford the cost of their medications.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Functional Dyspepsia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Functional Dyspepsia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Functional Dyspepsia Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Functional Dyspepsia, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Functional Dyspepsia epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Functional Dyspepsia is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Functional Dyspepsia market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Functional Dyspepsia market.

Report Highlights

  • In the coming years, the Functional Dyspepsia market is set to change due to the rising awareness of the disease and the Favorable Environment for New Anti-infective Modalities, which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Functional Dyspepsia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Functional Dyspepsia. The launch of emerging therapies will significantly impact the Functional Dyspepsia market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Functional Dyspepsia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Functional Dyspepsia Pipeline Analysis
  • Functional Dyspepsia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Functional Dyspepsia Report Key Strengths

  • 10 years Forecast
  • 7MM Coverage
  • Functional Dyspepsia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Functional Dyspepsia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Functional Dyspepsia Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Functional Dyspepsia total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings of the market across 7MM, and which country will have the largest Functional Dyspepsia market Size during the forecast period (2018–2030)?
  • At what CAGR, the Functional Dyspepsia market is expected to grow by 7MM during the forecast period (2018–2030)?
  • What would be the Functional Dyspepsia market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Functional Dyspepsia market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Functional Dyspepsia?
  • What is the historical Functional Dyspepsia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Functional Dyspepsia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Functional Dyspepsia?
  • Out of all 7MM countries, which country would have the largest prevalent population of Functional Dyspepsia during the forecast period (2018–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Functional Dyspepsia along with the approved therapy?
  • What are the current treatment guidelines for treating Functional Dyspepsia in the USA, Europe, and Japan?
  • What are the Functional Dyspepsia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Functional Dyspepsia?
  • How many therapies are developed by each company for the treatment of Functional Dyspepsia?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Functional Dyspepsia?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Functional Dyspepsia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Functional Dyspepsia and their status?
  • What are the key designations that have been granted for the emerging therapies for Functional Dyspepsia?
  • What are the global historical and forecasted market of Functional Dyspepsia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Functional Dyspepsia market.
  • To understand the future market competition in the Functional Dyspepsia market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Functional Dyspepsia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Functional Dyspepsia market.
  • To understand the future market competition in the Functional Dyspepsia market.

1. Key Insights

2. Report Introduction

3. Functional Dyspepsia Market Overview at a Glance

3.1. Market Share (%) Distribution of Functional Dyspepsia in 2018

3.2. Market Share (%) Distribution of Functional Dyspepsia in 2030

4. Executive Summary of Functional Dyspepsia

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Manifestations

5.3. Risk Factors

5.4. Pathogenesis

5.5. Subtypes

5.6. Diagnosis

5.6.1. Guidelines for Diagnosis

5.7. Differential Diagnosis

5.8. Treatment and Management

5.8.1. Treatment Guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Population of Functional Dyspepsia

6.3. Epidemiology of Functional Dyspepsia

6.4. The United States

6.4.1. Prevalent Cases of Functional Dyspepsia in the United States

6.4.2. Type-specific cases of Functional Dyspepsia in the United States

6.4.3. Age-specific Cases of Functional Dyspepsia in the United States

6.4.4. Gender-specific cases of Functional Dyspepsia in the United States

6.5. EU5

6.5.1. Germany

6.5.2. France

6.5.3. Italy

6.5.4. Spain

6.5.5. The United Kingdom

6.6. Japan

6.6.1. Prevalent Cases of Functional Dyspepsia in Japan

6.6.2. Type-specific cases of Functional Dyspepsia in Japan

6.6.3. Age-specific Cases of Functional Dyspepsia in Japan

6.6.4. Gender-specific cases of Functional Dyspepsia in Japan

7. Organizations contributing towards Functional Dyspepsia

8. Case Reports

9. Patient Journey

10. Marketed Therapies

10.1. ACOFIDE: Astellas Pharma & Zeria Pharmaceuticals

10.1.1. Product Description

10.1.2. Mechanism of action

10.1.3. Regulatory Milestones

10.1.4. Other Development Activities

10.1.5. Safety and Efficacy of Acofide

10.1.6. Side effects of ACOFIDE

10.1.7. Product Profile

11. Emerging Therapies

11.1. Other developmental assets

11.2. Motilitone (DA-9701): Dong-A ST

11.2.1. Drug Description

11.2.2. Clinical Development

11.2.3. Clinical Trials Information

11.2.4. Product Profile

12. Functional Dyspepsia: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Functional Dyspepsia in 7MM

12.3. Market Outlook

12.4. United States Market Size

12.4.1. Total Market Size of Functional Dyspepsia in the United States

12.4.2. Market Size of Functional Dyspepsia by Therapies

12.5. EU-5 Market

12.5.1. Germany

12.5.2. France

12.5.3. Italy

12.5.4. Spain

12.5.5. United Kingdom

12.6. Japan Market Size

12.6.1. Total Market Size of Functional Dyspepsia in Japan

12.6.2. Market Size of Functional Dyspepsia by Therapies in Japan

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. KOL Views

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Functional Dyspepsia, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Investigations for the Work-up of Functional Dyspepsia With Their Strengths and Weaknesses

Table 3: Total Prevalent Population of Functional Dyspepsia in 7MM (2018–2030)

Table 4: Prevalent Cases of Functional Dyspepsia in the United States (2018–2030)

Table 5: Type-specific cases of Functional Dyspepsia in the United States (2018–2030)

Table 6: Age-specific Cases of Functional Dyspepsia in the United States (2018–2030)

Table 7: Gender-specific cases of Functional Dyspepsia in the United States (2018–2030)

Table 8: Prevalent Cases of Functional Dyspepsia in Germany (2018–2030)

Table 9: Type-specific cases of Functional Dyspepsia in Germany (2018–2030)

Table 10: Age-specific Cases of Functional Dyspepsia in Germany (2018–2030)

Table 11: Gender-specific cases of Functional Dyspepsia in Germany (2018–2030)

Table 12: Prevalent Cases of Functional Dyspepsia in France (2018–2030)

Table 13: Type-specific cases of Functional Dyspepsia in France (2018–2030)

Table 14: Age-specific Cases of Functional Dyspepsia in France (2018–2030)

Table 15: Gender-specific cases of Functional Dyspepsia in France (2018–2030)

Table 16: Prevalent Cases of Functional Dyspepsia in Italy (2018–2030)

Table 17: Type-specific cases of Functional Dyspepsia in Italy (2018–2030)

Table 18: Age-specific Cases of Functional Dyspepsia in Italy (2018–2030)

Table 19: Gender-specific cases of Functional Dyspepsia in Italy (2018–2030)

Table 20: Prevalent Cases of Functional Dyspepsia in Spain (2018–2030)

Table 21: Type-specific cases of Functional Dyspepsia in Spain (2018–2030)

Table 22: Age-specific Cases of Functional Dyspepsia in Spain (2018–2030)

Table 23: Gender-specific cases of Functional Dyspepsia in Spain (2018–2030)

Table 24: Prevalent Cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Table 25: Type-specific cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Table 26: Age-specific Cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Table 27: Gender-specific cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Table 28: Prevalent Cases of Functional Dyspepsia in Japan (2018–2030)

Table 29: Type-specific cases of Functional Dyspepsia in Japan (2018–2030)

Table 30: Age-specific Cases of Functional Dyspepsia in Japan (2018–2030)

Table 31: Gender-specific cases of Functional Dyspepsia in Japan (2018–2030)

Table 32: Organizations Contributing Toward the Fight Against Functional Dyspepsia

Table 33: Motilitone, Clinical Trial Description, 2021

Table 34: 7 Major Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 35: The US Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 36: The US Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)

Table 37: The Germany Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 38: The Germany Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)

Table 39: The France Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 40: The France Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)

Table 41: The Italy Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 42: The Italy Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)

Table 43: The Spain Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 44: The Spain Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)

Table 45: The United Kingdom Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 46: The United Kingdom Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)

Table 47: The Japan Market Size of Functional Dyspepsia in USD million (2018–2030)

Table 48: The Japan Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)

List of Figures

Figure 1: Clinical Manifestations in Functional Dyspepsia

Figure 2: Risk factors Involved in Functional Dyspepsia

Figure 3: Various Mechanisms Involved in the Pathogenesis of Functional Dyspepsia

Figure 4: Subtypes of Functional Dyspepsia

Figure 5: Rome III Diagnostic Criteria for Functional Dyspepsia

Figure 6: Rome IV Diagnostic Criteria for Functional Dyspepsia

Figure 7: Differential Diagnosis of Functional Dyspepsia

Figure 8: Management Algorithm of Functional Dyspepsia

Figure 9: ACG/CAG Treatment Guidelines- Recommendations for Functional Dyspepsia

Figure 10: Total Prevalent Population of Functional Dyspepsia in 7MM (2018–2030)

Figure 11: Prevalence of Functional Dyspepsia and subtypes using symptom-based criteria (Rome IV)

Figure 12: Prevalent Cases of Functional Dyspepsia in the United States (2018–2030)

Figure 13: Type-specific cases of Functional Dyspepsia in the United States (2018–2030)

Figure 14: Age-specific Cases of Functional Dyspepsia in the United States (2018–2030)

Figure 15: Gender-specific cases of Functional Dyspepsia in the United States (2018–2030)

Figure 16: Prevalent Cases of Functional Dyspepsia in Germany (2018–2030)

Figure 17: Type-specific cases of Functional Dyspepsia in Germany (2018–2030)

Figure 18: Age-specific Cases of Functional Dyspepsia in Germany (2018–2030)

Figure 19: Gender-specific cases of Functional Dyspepsia in Germany (2018–2030)

Figure 20: Prevalent Cases of Functional Dyspepsia in France (2018–2030)

Figure 21: Type-specific cases of Functional Dyspepsia in France (2018–2030)

Figure 22: Age-specific Cases of Functional Dyspepsia in France (2018–2030)

Figure 23: Gender-specific cases of Functional Dyspepsia in France (2018–2030)

Figure 24: Prevalent Cases of Functional Dyspepsia in Italy (2018–2030)

Figure 25: Type-specific cases of Functional Dyspepsia in Italy (2018–2030)

Figure 26: Age-specific Cases of Functional Dyspepsia in Italy (2018–2030)

Figure 27: Gender-specific cases of Functional Dyspepsia in Italy (2018–2030)

Figure 28: Prevalent Cases of Functional Dyspepsia in Spain (2018–2030)

Figure 29: Type-specific cases of Functional Dyspepsia in Spain (2018–2030)

Figure 30: Age-specific Cases of Functional Dyspepsia in Spain (2018–2030)

Figure 31: Gender-specific cases of Functional Dyspepsia in Spain (2018–2030)

Figure 32: Prevalent Cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Figure 33: Type-specific cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Figure 34: Age-specific Cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Figure 35: Gender-specific cases of Functional Dyspepsia in the United Kingdom (2018–2030)

Figure 36: Prevalent Cases of Functional Dyspepsia in Japan (2018–2030)

Figure 37: Type-specific cases of Functional Dyspepsia in Japan (2018–2030)

Figure 38: Age-specific Cases of Functional Dyspepsia in Japan (2018–2030)

Figure 39: Gender-specific cases of Functional Dyspepsia in Japan (2018–2030)

Figure 40: 7 Major Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 41: The US Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 42: The US Market Size of Functional Dyspepsia by Therapies (2018–2030)

Figure 43: The Germany Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 44: The Germany Market Size of Functional Dyspepsia by Therapies (2018–2030)

Figure 45: The France Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 46: The France Market Size of Functional Dyspepsia by Therapies (2018–2030)

Figure 47: The Italy Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 48: The Italy Market Size of Functional Dyspepsia by Therapies (2018–2030)

Figure 49: The Spain Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 50: The Spain Market Size of Functional Dyspepsia by Therapies (2018–2030)

Figure 51: The United Kingdom Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 52: The United Kingdom Market Size of Functional Dyspepsia by Therapies (2018–2030)

Figure 53: The Japan Market Size of Functional Dyspepsia in USD million (2018–2030)

Figure 54: The Japan Market Size of Functional Dyspepsia by Therapies (2018–2030)

Figure 55: Overlapping symptoms and pathophysiology of Functional Dyspepsia, IBS, and GERD

• Astellas Pharma & Zeria Pharmaceuticals

• Dong-A ST

  • Tags:
  • Functional Dyspepsia market
  • Functional Dyspepsia market resear...
  • Functional Dyspepsia market insig...
  • Functional Dyspepsia market trends
  • Functional Dyspepsia market foreca...
  • Functional Dyspepsia market share
  • Functional Dyspepsia pipeline drug...
  • Functional Dyspepsia treatment al...
  • Functional Dyspepsia drugs
  • Functional Dyspepsia sales forecas...
  • Functional Dyspepsia market size
  • Functional Dyspepsia disease
  • Functional Dyspepsia epidemiology
  • Functional Dyspepsia

Forward to Friend

Need A Quote